Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival ...

Описание к видео Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival ...

Dr Do-Youn Oh speaks to ecancer about the three-year survival, safety, and extended long-term survivor (eLTS) analysis from the phase III TOPAZ-1 study of durvalumab plus chemotherapy in biliary tract cancer.

In this study, patients with advanced biliary tract cancer received either durvalumab or a placebo combined with gemcitabine and cisplatin every three weeks, followed by durvalumab or a placebo as monotherapy.

After 3 years of follow-up, durvalumab, gemcitabine, and cisplatin continued to demonstrate a clinically meaningful long-term survival benefit that was further improved in patients who achieved disease control.

Комментарии

Информация по комментариям в разработке

Похожие видео